Cargando…

Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial

BACKGROUND: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic evaluation was included. The main results showed no statistical evidence of a difference in either...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattarai, Nawaraj, Price, Christopher I, McMeekin, Peter, Javanbakht, Mehdi, Vale, Luke, Ford, Gary A, Shaw, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864331/
https://www.ncbi.nlm.nih.gov/pubmed/33724103
http://dx.doi.org/10.1177/17474930211006302
_version_ 1784655442908020736
author Bhattarai, Nawaraj
Price, Christopher I
McMeekin, Peter
Javanbakht, Mehdi
Vale, Luke
Ford, Gary A
Shaw, Lisa
author_facet Bhattarai, Nawaraj
Price, Christopher I
McMeekin, Peter
Javanbakht, Mehdi
Vale, Luke
Ford, Gary A
Shaw, Lisa
author_sort Bhattarai, Nawaraj
collection PubMed
description BACKGROUND: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic evaluation was included. The main results showed no statistical evidence of a difference in either thrombolysis volume (primary outcome) or 90-day dependency. However, counter-intuitive findings were observed with the intervention group showing fewer thrombolysis treatments but less dependency. AIMS: Cost-effectiveness of the PASTA intervention was examined relative to standard care. METHODS: A within trial cost-utility analysis estimated mean costs and quality-adjusted life years over 90 days’ time horizon. Costs were derived from resource utilization data for individual trial participants. Quality-adjusted life years were calculated by mapping modified Rankin scale scores to EQ-5D-3L utility tariffs. A post-hoc subgroup analysis examined cost-effectiveness when trial hospitals were divided into compliant and non-compliant with recommendations for a stroke specialist thrombolysis rota. RESULTS: The trial enrolled 1214 patients: 500 PASTA and 714 standard care. There was no evidence of a quality-adjusted life year difference between groups [0·007 (95% CI: −0·003 to 0·018)] but costs were lower in the PASTA group [−£1473 (95% CI: −£2736 to −£219)]. There was over 97.5% chance that the PASTA pathway would be considered cost-effective. There was no evidence of a difference in costs at seven thrombolysis rota compliant hospitals but costs at eight non-complaint hospitals costs were lower in PASTA with more dominant cost-effectiveness. CONCLUSIONS: Analyses indicate that the PASTA pathway may be considered cost-effective, particularly if deployed in areas where stroke specialist availability is limited. Trial Registration: ISRCTN12418919 www.isrctn.com/ISRCTN12418919
format Online
Article
Text
id pubmed-8864331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88643312022-02-24 Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial Bhattarai, Nawaraj Price, Christopher I McMeekin, Peter Javanbakht, Mehdi Vale, Luke Ford, Gary A Shaw, Lisa Int J Stroke Research BACKGROUND: The Paramedic Acute Stroke Treatment Assessment (PASTA) trial evaluated an enhanced emergency care pathway which aimed to facilitate thrombolysis in hospital. A pre-planned health economic evaluation was included. The main results showed no statistical evidence of a difference in either thrombolysis volume (primary outcome) or 90-day dependency. However, counter-intuitive findings were observed with the intervention group showing fewer thrombolysis treatments but less dependency. AIMS: Cost-effectiveness of the PASTA intervention was examined relative to standard care. METHODS: A within trial cost-utility analysis estimated mean costs and quality-adjusted life years over 90 days’ time horizon. Costs were derived from resource utilization data for individual trial participants. Quality-adjusted life years were calculated by mapping modified Rankin scale scores to EQ-5D-3L utility tariffs. A post-hoc subgroup analysis examined cost-effectiveness when trial hospitals were divided into compliant and non-compliant with recommendations for a stroke specialist thrombolysis rota. RESULTS: The trial enrolled 1214 patients: 500 PASTA and 714 standard care. There was no evidence of a quality-adjusted life year difference between groups [0·007 (95% CI: −0·003 to 0·018)] but costs were lower in the PASTA group [−£1473 (95% CI: −£2736 to −£219)]. There was over 97.5% chance that the PASTA pathway would be considered cost-effective. There was no evidence of a difference in costs at seven thrombolysis rota compliant hospitals but costs at eight non-complaint hospitals costs were lower in PASTA with more dominant cost-effectiveness. CONCLUSIONS: Analyses indicate that the PASTA pathway may be considered cost-effective, particularly if deployed in areas where stroke specialist availability is limited. Trial Registration: ISRCTN12418919 www.isrctn.com/ISRCTN12418919 SAGE Publications 2021-04-07 2022-03 /pmc/articles/PMC8864331/ /pubmed/33724103 http://dx.doi.org/10.1177/17474930211006302 Text en © 2021 World Stroke Organization https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research
Bhattarai, Nawaraj
Price, Christopher I
McMeekin, Peter
Javanbakht, Mehdi
Vale, Luke
Ford, Gary A
Shaw, Lisa
Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
title Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
title_full Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
title_fullStr Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
title_full_unstemmed Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
title_short Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial
title_sort cost-effectiveness of an enhanced paramedic acute stroke treatment assessment (pasta) during emergency stroke care: economic results from a pragmatic cluster randomized trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864331/
https://www.ncbi.nlm.nih.gov/pubmed/33724103
http://dx.doi.org/10.1177/17474930211006302
work_keys_str_mv AT bhattarainawaraj costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial
AT pricechristopheri costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial
AT mcmeekinpeter costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial
AT javanbakhtmehdi costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial
AT valeluke costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial
AT fordgarya costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial
AT shawlisa costeffectivenessofanenhancedparamedicacutestroketreatmentassessmentpastaduringemergencystrokecareeconomicresultsfromapragmaticclusterrandomizedtrial